Terri E. Weaver, PhD, RN, on Efficacy of Solriamfetol for Treating Symptoms of Obstructive Sleep Apnea
In this video, Terri E. Weaver, PhD, RN, talks about the effectiveness of solriamfetol in improving daily functioning, reducing daytime sleepiness, and enhancing work productivity.
- Weaver T, Pepin JL, Schwab R, et al. Long-term effects of solriamfetol on excessive daytime sleepiness and functional outcomes in participants with OSA. Paper presented at: CHEST 2020; October 18-21, 2020; Virtual. https://journal.chestnet.org/article/S0012-3692(20)34156-8/fulltext
Terri E. Weaver, PhD, RN, is dean and professor in the Department of Behavioral Nursing Science in the College of Nursing and professor in the Division of Pulmonary, Critical Care, Sleep, and Allergy in the Department of Medicine in the College of Medicine at the University of Illinois at Chicago.
My name is Terri Weaver, I am Dean and professor at the University of Illinois Chicago College of Nursing.
This was a study to look at the effectiveness as opposed to the efficacy of solriamfetol with particular outcomes of daily functioning, daytime sleepiness, and also work productivity, along with perception of change by the patient and also the clinician.
It is approved for daytime sleepiness and patients with obstructive sleep apnea. It’s also approved for the treatment of sleepiness and narcolepsy. It is approved for 3 doses—75 mg, 150 mg, and 300 mg.
The findings showed that when this was evaluated, especially with a withdrawal phase that included a placebo, that the efficacy of solriamfetol was maintained long term, 40 weeks out.
So, the initial studies with clinical trial that was done to prove efficacy of solriamfetol showed that it was efficacious for daytime sleepiness, daily functioning, and work productivity. This study showed that efficacy was maintained long term, which was clinical effectiveness. And so, it has both efficacy and effectiveness
A component of the study was a withdrawal phase where individuals who were on doses that treated their sleepiness, when you withdrew that, in fact, they were still able to see the benefit in several outcomes that were the case with regard to the initial evaluation of the agent and that those who were placed on placebo during that time had a decline.
Thank you for the opportunity to share our work, greatly appreciate it.